Project

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First Line chemotherapy (DeLLphi-304)

Ongoing - recruitment active · 2023 until 2025

Früh Martin, Hutter Franziska, Quinter Janine